Description
DESCRIPTION (provided by applicant): Approximately 80% of patients with chemo-resistant intermediate grade non-Hodgkin's lymphoma (NHL) will relapse following high-dose chemotherapy with autologous stem cell transplantation (ASCT). Our ability to further intensify chemotherapy to improve the outcome of ASCT has reached a plateau, necessitating a need for development of novel therapeutic strategies. Rituximab is a chimeric monoclonal antibody directed against CD20, found on most B-cell NHL. As a single agent, rituximab is modestly effective with
| Status | Finished |
|---|---|
| Effective start/end date | 9/30/02 → 9/29/05 |
Funding
- National Institutes of Health: $328,188.00
- National Institutes of Health: $328,188.00
Fingerprint
Cell- and Tissue-Based Therapy
Non-Hodgkin's Lymphoma
Stem Cells
Stem Cell Transplantation
Transplants
Drug Therapy
B-Cell Lymphoma
Monoclonal Antibodies
Recurrence
Rituximab
Therapeutics
ASJC
- Medicine(all)